Nuvation Bio NUVB Derivative Liabilities - Fair Value
Derivative Liabilities - Fair Value at other companies
Other financials
Where this comes from
Reported directly by Nuvation Bio in its filing.
Tagged under the XBRL concept us-gaap:DerivativeFairValueOfDerivativeLiability.
The official record: Nuvation Bio’s 10-K, filed March 2, 2026, on SEC EDGAR. View the filing →
Ask your AI about Nuvation Bio's derivative liabilities - fair value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Nuvation Bio's derivative liabilities - fair value?
- Nuvation Bio (NUVB) reported derivative liabilities - fair value of $2.87M in Q4 2025.
- How has Nuvation Bio's derivative liabilities - fair value changed year-over-year?
- Nuvation Bio's derivative liabilities - fair value increased by 39.6% year-over-year, from $2.05M to $2.87M.
- What is the long-term trend for Nuvation Bio's derivative liabilities - fair value?
- Over 4 years (2021 to 2025), Nuvation Bio's derivative liabilities - fair value has grown at a -28.6% compound annual growth rate (CAGR), from $11.04M to $2.87M.
- What does derivative liabilities - fair value mean?
- This metric represents the total fair market value of all derivative contracts currently in a liability position for the institution. It reflects the potential cash outflow required if these contracts were settled at the current reporting date. Monitoring this value is essential for assessing the bank's exposure to market volatility and counterparty risk.